North America Ablation Devices Market size crossed USD 3 billion in 2021 and is anticipated to expand at a CAGR of 10.9% CAGR from 2022 to 2028. The industry growth is primarily attributed to growing preference for minimally invasive procedures in the region. Additionally, numerous benefits offered by such minimally invasive procedures over open surgical procedure will positively influence the market growth. Furthermore, the rising prevalence of atrial fibrillation in the general population will increase the number of cardiac ablation procedures.

Get more details on this report - Request Free Sample PDF

Rising prevalence of cancer and other chronic diseases across the region coupled with increasing healthcare expenditure will stimulate the market demand. Significant increase in number of cancer patients have been observed in North America where radiofrequency ablation devices are majorly use for treatment of cancer.

North America Market, By Product

Get more details on this report - Request Free Sample PDF

The radiofrequency devices segment will showcase around 10.5% growth rate during the forecast period. Increasing use of devices in the field of oncology, cosmetology, cardiology, and others for effective treatment will augment demand for radiofrequency devices in the market. Additionally, various advantages associated with use of radiofrequency devices such as quick relief, high success rate in the treatment of atrial fibrillation will contribute to the market revenue.

North America Market, By End-use

The hospital’s segment held around 50% North America ablation devices market share in 2021, due to increasing prevalence of cardiac arrhythmia disorders globally coupled with increasing geriatric pool. Additionally, owing to various advantages such as availability of skilled workforce and presence of sophisticated healthcare infrastructure will further drive the market expansion. Furthermore, expanding number of hospitals and growing number of patient visits leading to high rate of treatment performed in hospital settings.

North America Market, By Country

U.S. ablation devices market revenue was more than USD 2.5 billion in 2021 and will grow at 10.9% CAGR through 2028. Rapid adoption of unhealthy lifestyle choices such as excessive tobacco consumption, alcohol drinking, and smoking are leading to an increasing prevalence of cardiovascular disorders. According to the CDC, every year in U.S., nearly 6.5 million deaths are reported due to cardiovascular diseases. Furthermore, rising awareness regarding cardiovascular diseases and availability of advanced treatment options will drive the market growth.

Competitive Industry Landscape

Some of the leading companies involved in the North America ablation devices market include Abbott Laboratories, AngioDynamics, Inc, AtriCure Inc, Biotronik SE & Co. KG, Bausch & Lomb Incorporated, Boston Scientific Corporation, CONMED Corporation, Medtronic plc, Elekta AB, Olympus Corporation, Varian, and Ethicon, Inc (Johnson & Johnson).

These notable market players are undertaking several growth strategies to broaden market share through collaboration, acquisitions, and novel product launches. For instance, in January 2022, Abbott has received U.S. FDA clearance for its new cardiac mapping platform EnSite X EP System with EnSite Omnipolar Technology (OT). The device that helps physicians to treat abnormal heart rhythms, i.e., cardiac arrhythmias. This has helped company to expand its product offering in U.S. and across Europe and strengthen its position in the market.